Table 2.
Evaluation of efficacy of neoadjuvant Afatinib (n = 47)
| Variables | No. of patient (%) |
|---|---|
| Duration of NAT, cycle (range) | 2.7 (1-9) |
| Surgery performed | 33 (70.2) |
| Tumor response | |
| PR | 33 (70.2) |
| SD | 11 (23.4) |
| PD | 2 (4.3) |
| No Re-evaluation | 1 (2.1) |
| ORR (%) | 70.2 |
| DCR (%) | 93.6 |
| MTD regression, % (range) | 36.0 (−28–78) |
| cN downstaging | 37 (78.7) |
| ypN downstaging # | 19 (57.6) |
| ypTNM # | |
| 0/I | 14 (42.4) |
| II | 5 (15.2) |
| III | 14 (42.4) |
| Type of surgery # | |
| Thoracotomy | 16 (48.5) |
| VATS | 17 (51.5) |
| Surgical resection # | |
| Lobectomy | 28 (84.8) |
| Bi-Lobectomy | 5 (15.2) |
| Resection # | |
| R0 | 29 (87.9) |
| R1 | 1 (3.0) |
| R2 | 3 (9.1) |
| Residual tumor cell, % (range) # | 57.3 (0-95) |
| Residual tumor cell ≤ 60% # | 17 (51.5) |
| Pathologic regression # | |
| pCR | 1 (3.0) |
| MPR | 3 (9.1) |
| Non-MPR | 30 (90.9) |
| Mean operation time (hour) | 2.4 |
| Mean blood loss (mL) | 100 |
| Mean hospital stay postoperatively, day (range) | 6.6 |
| Mean chest drainage time, day (range) | 12.5 |
#: Patients received neoadjuvant therapy followed by surgery.
DCR disease control rate, MPR major pathological response, MTD maximum tumor dimension, NAT neoadjuvant Afatinib treatment, ORR objective response rate, pCR pathological complete response, PD progressive disease, PR partial response, SD stable disease.